PressJuly 21, 2022 Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
PressJuly 20, 2022 Delic Labs President and CSO Dr. Markus Roggen Named to Cannabis Scientist Power List for Third Consecutive Year
PressJuly 20, 2022 Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
PressJuly 13, 2022 Albert Labs Files US Provisional Patent Application for Psilocybe And Other Mycelia
PressJuly 12, 2022 Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
PressJuly 8, 2022 Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
PressJuly 7, 2022 Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023
PressJuly 6, 2022 CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds
PressJuly 5, 2022 Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate
PressJuly 1, 2022 atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
PressJune 28, 2022 Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA
